Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

D. Western Therapeutics Institute

JASDAQ:4576
Snowflake Description

Excellent balance sheet with acceptable track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4576
JASDAQ
¥8B
Market Cap
  1. Home
  2. JP
  3. Pharmaceuticals & Biotech
Company description

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on developing drugs to serve patients worldwide. The last earnings update was 51 days ago. More info.


Add to Portfolio Compare Print
  • D. Western Therapeutics Institute has significant price volatility in the past 3 months.
4576 Share Price and Events
7 Day Returns
-11.1%
JASDAQ:4576
-7.7%
JP Biotechs
-8.9%
JP Market
1 Year Returns
-38%
JASDAQ:4576
-30.1%
JP Biotechs
-17.9%
JP Market
4576 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
D. Western Therapeutics Institute (4576) -11.1% -26.4% -51.9% -38% -45.5% -61.8%
JP Biotechs -7.7% -14.9% -31.4% -30.1% -2.4% 12.5%
JP Market -8.9% -12.1% -22.9% -17.9% -10.5% -14%
1 Year Return vs Industry and Market
  • 4576 underperformed the Biotechs industry which returned -30.1% over the past year.
  • 4576 underperformed the Market in Japan which returned -17.9% over the past year.
Price Volatility
4576
Industry
5yr Volatility vs Market

Value

 Is D. Western Therapeutics Institute undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of D. Western Therapeutics Institute to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for D. Western Therapeutics Institute.

JASDAQ:4576 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 7.2%
Perpetual Growth Rate 10-Year JP Government Bond Rate -0.1%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for JASDAQ:4576
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year JP Govt Bond Rate -0.1%
Equity Risk Premium S&P Global 6.3%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.189 (1 + (1- 30.86%) (5.86%))
1.159
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.16
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.09% + (1.159 * 6.33%)
7.25%

Discounted Cash Flow Calculation for JASDAQ:4576 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for D. Western Therapeutics Institute is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

JASDAQ:4576 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 7.25%)
2020 273.50 Est @ 67.1% 255.03
2021 401.91 Est @ 46.95% 349.43
2022 533.87 Est @ 32.84% 432.81
2023 656.44 Est @ 22.96% 496.22
2024 761.75 Est @ 16.04% 536.92
2025 847.10 Est @ 11.2% 556.74
2026 913.30 Est @ 7.82% 559.69
2027 963.02 Est @ 5.44% 550.29
2028 999.46 Est @ 3.78% 532.52
2029 1,025.66 Est @ 2.62% 509.56
Present value of next 10 years cash flows ¥4,779.00
JASDAQ:4576 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= ¥1,025.66 × (1 + -0.09%) ÷ (7.25% – -0.09%)
¥13,968.73
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥13,968.73 ÷ (1 + 7.25%)10
¥6,939.84
JASDAQ:4576 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥4,779.00 + ¥6,939.84
¥11,718.84
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥11,718.84 / 26.28
¥446
JASDAQ:4576 Discount to Share Price
Calculation Result
Value per share (JPY) From above. ¥446.00
Current discount Discount to share price of ¥312.00
= -1 x (¥312.00 - ¥446.00) / ¥446.00
30%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price D. Western Therapeutics Institute is available for.
Intrinsic value
30%
Share price is ¥312 vs Future cash flow value of ¥446
Current Discount Checks
For D. Western Therapeutics Institute to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • D. Western Therapeutics Institute's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • D. Western Therapeutics Institute's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for D. Western Therapeutics Institute's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are D. Western Therapeutics Institute's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
JASDAQ:4576 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in JPY ¥5.06
JASDAQ:4576 Share Price ** JASDAQ (2020-04-03) in JPY ¥312
Japan Biotechs Industry PE Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 61.64x
Japan Market PE Ratio Median Figure of 3,072 Publicly-Listed Companies 11.52x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of D. Western Therapeutics Institute.

JASDAQ:4576 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= JASDAQ:4576 Share Price ÷ EPS (both in JPY)

= 312 ÷ 5.06

61.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • D. Western Therapeutics Institute is good value based on earnings compared to the JP Biotechs industry average.
  • D. Western Therapeutics Institute is overvalued based on earnings compared to the Japan market.
Price based on expected Growth
Does D. Western Therapeutics Institute's expected growth come at a high price?
Raw Data
JASDAQ:4576 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 61.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Asia Biotechs Industry PEG Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 1.97x
Japan Market PEG Ratio Median Figure of 1,282 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for D. Western Therapeutics Institute, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on D. Western Therapeutics Institute's assets?
Raw Data
JASDAQ:4576 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in JPY ¥53.02
JASDAQ:4576 Share Price * JASDAQ (2020-04-03) in JPY ¥312
Japan Biotechs Industry PB Ratio Median Figure of 21 Publicly-Listed Biotechs Companies 4.06x
Japan Market PB Ratio Median Figure of 3,576 Publicly-Listed Companies 0.8x
JASDAQ:4576 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= JASDAQ:4576 Share Price ÷ Book Value per Share (both in JPY)

= 312 ÷ 53.02

5.89x

* Primary Listing of D. Western Therapeutics Institute.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • D. Western Therapeutics Institute is overvalued based on assets compared to the JP Biotechs industry average.
X
Value checks
We assess D. Western Therapeutics Institute's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. D. Western Therapeutics Institute has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is D. Western Therapeutics Institute expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as D. Western Therapeutics Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
35.3%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is D. Western Therapeutics Institute expected to grow at an attractive rate?
  • Unable to compare D. Western Therapeutics Institute's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare D. Western Therapeutics Institute's earnings growth to the Japan market average as no estimate data is available.
  • Unable to compare D. Western Therapeutics Institute's revenue growth to the Japan market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
JASDAQ:4576 Future Growth Rates Data Sources
Data Point Source Value (per year)
Japan Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 35.3%
Japan Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 21.6%
Japan Market Earnings Growth Rate Market Cap Weighted Average 9.1%
Japan Market Revenue Growth Rate Market Cap Weighted Average 3.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
JASDAQ:4576 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
JASDAQ:4576 Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
JASDAQ:4576 Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2019-12-31 580 175 133
2019-09-30 538 -61
2019-06-30 537 -127 -248
2019-03-31 514 -412
2018-12-31 292 -540 -748
2018-09-30 267 -798
2018-06-30 293 -635 -605
2018-03-31 279 -1,578
2017-12-31 254 -797 -1,563
2017-09-30 239 -1,398
2017-06-30 151 -610 -1,464
2017-03-31 126 -385

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if D. Western Therapeutics Institute is high growth as no earnings estimate data is available.
  • Unable to determine if D. Western Therapeutics Institute is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
JASDAQ:4576 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from D. Western Therapeutics Institute Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

JASDAQ:4576 Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
JASDAQ:4576 Past Financials Data
Date (Data in JPY Millions) EPS *
2019-12-31 5.06
2019-09-30 -2.32
2019-06-30 -9.44
2019-03-31 -15.68
2018-12-31 -28.47
2018-09-30 -30.38
2018-06-30 -23.04
2018-03-31 -60.09
2017-12-31 -59.87
2017-09-30 -54.33
2017-06-30 -57.73
2017-03-31 -15.46

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if D. Western Therapeutics Institute will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine D. Western Therapeutics Institute's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. D. Western Therapeutics Institute's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess D. Western Therapeutics Institute's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Japan market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Japan market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
D. Western Therapeutics Institute has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has D. Western Therapeutics Institute performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare D. Western Therapeutics Institute's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • D. Western Therapeutics Institute has delivered over 20% year on year earnings growth in the past 5 years.
  • D. Western Therapeutics Institute has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.
  • D. Western Therapeutics Institute has become profitable in the last year making it difficult to compare the Asia Biotechs industry average.
Earnings and Revenue History
D. Western Therapeutics Institute's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from D. Western Therapeutics Institute Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

JASDAQ:4576 Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 580.00 133.00 188.00 249.00
2019-09-30 538.00 -61.00 208.00 388.00
2019-06-30 537.00 -248.00 231.00 566.00
2019-03-31 514.00 -412.00 263.00 683.00
2018-12-31 292.00 -748.00 268.00 795.00
2018-09-30 267.00 -798.00 269.00 823.00
2018-06-30 293.00 -605.00 269.00 753.00
2018-03-31 279.00 -1,578.00 263.00 675.00
2017-12-31 254.00 -1,563.00 276.00 603.00
2017-09-30 239.00 -1,398.00 276.00 459.00
2017-06-30 151.00 -1,464.00 276.00 338.00
2017-03-31 126.00 -385.00 266.00 284.00
2016-12-31 168.00 -253.00 260.00 226.00
2015-12-31 61.00 -296.00 195.00 143.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • D. Western Therapeutics Institute has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • D. Western Therapeutics Institute used its assets more efficiently than the JP Biotechs industry average last year based on Return on Assets.
  • D. Western Therapeutics Institute has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).
X
Past performance checks
We assess D. Western Therapeutics Institute's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
D. Western Therapeutics Institute has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is D. Western Therapeutics Institute's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up D. Western Therapeutics Institute's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • D. Western Therapeutics Institute is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • D. Western Therapeutics Institute's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of D. Western Therapeutics Institute's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from D. Western Therapeutics Institute Company Filings, last reported 3 months ago.

JASDAQ:4576 Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 1,408.00 480.00 1,540.00
2019-09-30 1,397.00 510.00 1,518.00
2019-06-30 1,421.00 540.00 1,580.00
2019-03-31 1,443.00 570.00 1,606.00
2018-12-31 1,299.00 600.00 1,584.00
2018-09-30 1,498.00 600.00 1,670.00
2018-06-30 1,715.00 600.00 1,888.00
2018-03-31 1,899.00 600.00 2,083.00
2017-12-31 2,094.00 600.00 2,132.00
2017-09-30 2,336.00 600.00 2,190.00
2017-06-30 2,446.00 600.00 2,319.00
2017-03-31 3,555.00 600.00 3,886.00
2016-12-31 2,876.00 0.00 2,644.00
2015-12-31 2,111.00 0.00 1,929.00
  • D. Western Therapeutics Institute's level of debt (34.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if D. Western Therapeutics Institute's debt level has increased without past 5-year debt data.
  • Debt is well covered by operating cash flow (36.5%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 23.4x coverage).
X
Financial health checks
We assess D. Western Therapeutics Institute's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. D. Western Therapeutics Institute has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is D. Western Therapeutics Institute's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from D. Western Therapeutics Institute dividends.
If you bought ¥2,000 of D. Western Therapeutics Institute shares you are expected to receive ¥0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate D. Western Therapeutics Institute's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate D. Western Therapeutics Institute's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
JASDAQ:4576 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Asia Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 53 Stocks 0.7%
Japan Market Average Dividend Yield Market Cap Weighted Average of 2988 Stocks 3%
Japan Minimum Threshold Dividend Yield 10th Percentile 1%
Japan Bottom 25% Dividend Yield 25th Percentile 1.8%
Japan Top 25% Dividend Yield 75th Percentile 4.2%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

JASDAQ:4576 Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as D. Western Therapeutics Institute has not reported any payouts.
  • Unable to verify if D. Western Therapeutics Institute's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of D. Western Therapeutics Institute's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as D. Western Therapeutics Institute has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess D. Western Therapeutics Institute's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can D. Western Therapeutics Institute afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. D. Western Therapeutics Institute has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of D. Western Therapeutics Institute's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Yuichi Hidaka
AGE 46
CEO Bio

Mr. Yuichi Hidaka has been President of D.Western Therapeutics Institute, Inc.(DWTI) since December 2008 and serves as its Chief Executive Officer. Mr. Hidaka served as Manager of General Affairs Department of DWTI since July 2006. He joined Sanwa Bank (Mitsubishi Tokyo UFJ Bank) in April 1996. He has been a Representative Director of D.Western Therapeutics Institute, Inc. since December 2008. He served as Executive Director of DWTI since April 2007.

CEO Compensation
  • Insufficient data for Yuichi to compare compensation growth.
  • Insufficient data for Yuichi to establish whether their remuneration is reasonable compared to companies of similar size in Japan.
Management Team

Hiroyoshi Hidaka

TITLE
Founder
AGE
81
TENURE
21.2 yrs

Yuichi Hidaka

TITLE
President
AGE
46

Tetsuya Kawakami

TITLE
GM of Administration Division & Director
AGE
54
Board of Directors Tenure

Average tenure and age of the D. Western Therapeutics Institute board of directors in years:

9
Average Tenure
55.5
Average Age
  • The tenure for the D. Western Therapeutics Institute board of directors is about average.
Board of Directors

Hiroyoshi Hidaka

TITLE
Founder
AGE
81
TENURE
7.8 yrs

Yuichi Hidaka

TITLE
President
AGE
46
TENURE
11.3 yrs

Tetsuya Kawakami

TITLE
GM of Administration Division & Director
AGE
54
TENURE
6.1 yrs

Yoshiyuki Yamakawa

TITLE
Outside Director
AGE
57
TENURE
10.1 yrs

Tasuku Honjyo

TITLE
Member of Scientific Advisory Board

Masaaki Suzuki

TITLE
Member of Scientific Advisory Board

Masato Shibuya

TITLE
Member of Scientific Advisory Board

Arata Uemura

TITLE
Member of Scientific Advisory Board

Anthony Means

TITLE
Member of Scientific Advisory Board

Walter Chazin

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (¥) Value (¥)
X
Management checks
We assess D. Western Therapeutics Institute's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. D. Western Therapeutics Institute has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on developing drugs to serve patients worldwide. The company offers GLANATEC, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM staining and peeling. It is also developing WP-1303(H-1129), which is in Phase III clinical trials to treat glaucoma/ocular hypertension; H-1337, a multikinase inhibitor that has completed Phase I/IIa clinical trials for the treatment of glaucoma/ocular hypertension; and K-134, an anti-platelet, which has completed Phase IIb trials to treat arteriosclerosis obliterans. The company was founded in 1999 and is headquartered in Nagoya, Japan.

Details
Name: D. Western Therapeutics Institute, Inc.
4576
Exchange: JASDAQ
Founded: 1999
¥8,197,862,400
26,275,200
Website: http://www.dwti.co.jp
Address: D. Western Therapeutics Institute, Inc.
CK21 Hirokoujifushimi Building,
7th Floor,
Nagoya,
Aichi, 460-0003,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
JASDAQ 4576 Common Shares TSE JASDAQ JP JPY 23. Oct 2009
DB 6DW Common Shares Deutsche Boerse AG DE EUR 23. Oct 2009
Number of employees
Current staff
Staff numbers
17
D. Western Therapeutics Institute employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/04 15:30
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/02/13
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.